Traded on Nasdaq Capital Market, stock symbol EYEG, EyeGate is a clinical-stage specialty pharmaceutical company that develops and commercializes products using two proprietary platform technologies for treating diseases and disorders of the eye. Our most advanced platform is based on a crosslinked thiolated carboxymethyl hyaluronic acid (“CMHA-S”), a modified form of the natural polymer hyaluronic acid (“HA”), which is a gel that possesses unique physical and chemical properties such as hydrating and healing when applied to the ocular surface. Our first CMHA-S-based product candidate, the EyeGate Ocular Bandage Gel (“OBG”), is a topically applied eye drop formulation that has completed its first-in-man clinical trial for the healing and lubricating of large epithelial defects following treatment after photorefractive keratectomy (“PRK”) surgery. Our initial product candidate from our second platform is EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, that is delivered into the ocular tissues through our proprietary innovative iontophoresis drug delivery system, the EyeGate® II Delivery System. More than 2,400 treatments have been administered to date using our EyeGate® II Delivery System in clinical trials. EGP-437 is currently in clinical development for the treatment of various inflammatory conditions of the eye, including ocular inflammation and pain in post-surgical cataract patients and the treatment of uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea. EyeGate has entered into two exclusive, worldwide licensing agreements with subsidiaries of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) (“Valeant”) through which we have granted Valeant an exclusive, worldwide commercial and manufacturing rights to the EGP-437 combination product for the treatment of uveitis and post-operative ocular inflammation and pain in ocular surgery patients.